Sign In
Buy BIVI
$1.65
-0.0500 (-2.94%)
At Close: Jun 03, 2026
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioVie Inc. (BIVI)
12:00pm, Monday, 18'th Mar 2024
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming March 19, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investor
NEW YORK, NY / ACCESSWIRE / March 18, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a potential recovery under the federal securities laws, follow
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
10:55am, Tuesday, 12'th Mar 2024
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wa
BioVie to kick off Phase 2b trial for lead asset in Parkinson's disease in late-summer
08:56am, Monday, 11'th Mar 2024
BioVie Inc (NASDAQ:BIVI) told investors it has secured sufficient funds through a recently completed financing to progress its near-term clinical priority, developing its lead asset NE3107 for Parkins
Why Is BioVie (BIVI) Stock Up 100% Today?
10:57am, Friday, 01'st Mar 2024
BioVie (NASDAQ: BIVI ) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107. NE3107 is BioVie's inhibitor of inflammatory activation of ERK and NFkB.
BioVie shares surge on lead asset NE3107's potential to improve Parkinson's Disease symptoms
09:49am, Friday, 01'st Mar 2024
BioVie Inc (NASDAQ:BIVI) shares surged 130% in early trade on Friday after the company revealed that its lead asset NE3107 has demonstrated the potential to improve motor and non-motor symptoms in pat
BioVie Inc. (BIVI) Loses -46.95% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
11:18am, Monday, 11'th Dec 2023
The heavy selling pressure might have exhausted for BioVie Inc. (BIVI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analyst
BioVie (BIVI) Falls 61% Despite Upbeat Alzheimer's Study Data
12:01pm, Thursday, 30'th Nov 2023
BioVie (BIVI) stock plunges 61% in spite of positive phase III Alzheimer's Disease study results due to significant study conduct violations and protocol deviations reported by the company.
Why Is BioVie (BIVI) Stock Down 63% Today?
11:38am, Wednesday, 29'th Nov 2023
BioVie (NASDAQ: BIVI ) stock is falling on Wednesday after the company released data from a Phase 3 clinical trial of its Alzheimer's Disease treatment candidate NE3107. Unfortunately for investors in
BioVie reports efficacy data from NE3107 Phase 3 trial for Alzheimer's Disease
08:48am, Wednesday, 29'th Nov 2023
BioVie Inc (NASDAQ:BIVI), the clinical-stage company specializing in drug therapies for neurological disorders, revealed new results from the Phase 3 trial of NE3107 in patients with mild to moderate
BioVie: Cautiously Optimistic Ahead Of Phase 3 Alzheimer's Data Unblinding
08:12pm, Wednesday, 22'nd Nov 2023
Blinded Phase 3 data of NE3107 in Alzheimer's appear to indicate robust cognitive and biomarker efficacy. Market is significantly undervaluing the probability of a successful data unblinding expected
BioVie presents positive safety data from Phase 2 liver disease trial
09:14am, Monday, 13'th Nov 2023
BioVie Inc (NASDAQ:BIVI) has presented data from its Phase 2b trial evaluating the efficacy and safety of its drug candidate BIV201 for liver disease at The American Association for the Study of Liver
BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET
08:00am, Monday, 30'th Oct 2023
Management and Key Opinion Leader to Highlight Recent Data on NE3017 Presented at CTAD Conference Management and Key Opinion Leader to Highlight Recent Data on NE3017 Presented at CTAD Conference
BioVie to present clinical safety data from ascites Phase 2 trial at AASLD in November
08:53am, Thursday, 26'th Oct 2023
BioVie Inc (NASDAQ:BIVI) has announced that clinical safety data from its Phase 2 open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, in
BioVie says blinded data points to hopeful Alzheimer's treatment potential
02:19pm, Wednesday, 25'th Oct 2023
BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston suggests its drug candidate, NE3107, may have a significant imp
